World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders.

IF 3 4区医学 Q2 PSYCHIATRY

World Journal of Biological Psychiatry Pub Date : 2023-04-24 DOI:10.1080/15622975.2023.2179663

Hubertus Himmerich, Yael Doreen Lewis, Chiara Conti, Hiba Mutwalli, Andreas Karwautz, Jan Magnus Sjögren, María Mercedes Uribe Isaza, Marta Tyszkiewicz-Nwafor, Martin Aigner, Susan L McElroy, Janet Treasure, Siegfried Kasper

{"title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders.","authors":"Hubertus Himmerich, Yael Doreen Lewis, Chiara Conti, Hiba Mutwalli, Andreas Karwautz, Jan Magnus Sjögren, María Mercedes Uribe Isaza, Marta Tyszkiewicz-Nwafor, Martin Aigner, Susan L McElroy, Janet Treasure, Siegfried Kasper","doi":"10.1080/15622975.2023.2179663","DOIUrl":null,"url":null,"abstract":"Objectives: This 2023 update of the WFSBP guidelines for the pharmacological treatment of eating disorders (EDs) reflects the latest diagnostic and psychopharmacological progress and the improved WFSBP recommendations for the assessment of the level of evidence (LoE) and the grade of recommendation (GoR).Methods: The WFSBP Task Force EDs reviewed the relevant literature and provided a timely grading of the LoE and the GoR.Results: In anorexia nervosa (AN), only a limited recommendation (LoE: A; GoR: 2) for olanzapine can be given, because the available evidence is restricted to weight gain, and its effect on psychopathology is less clear. In bulimia nervosa (BN), the current literature prompts a recommendation for fluoxetine (LoE: A; GoR: 1) or topiramate (LoE: A; GoR: 1). In binge-eating disorder (BED), lisdexamfetamine (LDX; LoE: A; GoR: 1) or topiramate (LoE: A; GoR: 1) can be recommended. There is only sparse evidence for the drug treatment of avoidant restrictive food intake disorder (ARFID), pica, and rumination disorder (RD).Conclusion: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.","PeriodicalId":49358,"journal":{"name":"World Journal of Biological Psychiatry","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15622975.2023.2179663","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 7

Abstract

Objectives: This 2023 update of the WFSBP guidelines for the pharmacological treatment of eating disorders (EDs) reflects the latest diagnostic and psychopharmacological progress and the improved WFSBP recommendations for the assessment of the level of evidence (LoE) and the grade of recommendation (GoR).

Methods: The WFSBP Task Force EDs reviewed the relevant literature and provided a timely grading of the LoE and the GoR.

Results: In anorexia nervosa (AN), only a limited recommendation (LoE: A; GoR: 2) for olanzapine can be given, because the available evidence is restricted to weight gain, and its effect on psychopathology is less clear. In bulimia nervosa (BN), the current literature prompts a recommendation for fluoxetine (LoE: A; GoR: 1) or topiramate (LoE: A; GoR: 1). In binge-eating disorder (BED), lisdexamfetamine (LDX; LoE: A; GoR: 1) or topiramate (LoE: A; GoR: 1) can be recommended. There is only sparse evidence for the drug treatment of avoidant restrictive food intake disorder (ARFID), pica, and rumination disorder (RD).

Conclusion: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.

查看原文本刊更多论文

世界生物精神病学学会联合会(WFSBP) 2023年关于饮食失调药物治疗的指南更新。

2023年更新的WFSBP饮食失调(EDs)药理学治疗指南反映了最新的诊断和精神药理学进展，以及改进的WFSBP证据水平(LoE)和推荐等级(GoR)评估建议。方法:WFSBP工作组查阅相关文献，及时对LoE和GoR进行评分。结果:在神经性厌食症(AN)中，只有有限的推荐(LoE: a;可给予奥氮平的GoR: 2)，因为现有证据仅限于体重增加，其对精神病理的影响尚不清楚。在神经性贪食症(BN)中，目前的文献建议使用氟西汀(LoE: a;GoR: 1)或托吡酯(LoE: A;GoR: 1).在暴食症(BED)中，利地安非他明(LDX;爱:一个;GoR: 1)或托吡酯(LoE: A;GoR: 1)可推荐使用。对于回避性限制性食物摄入障碍(ARFID)、异食癖(pica)和反刍障碍(RD)的药物治疗，只有很少的证据。结论:BN、氟西汀、托吡酯、BED、LDX、托吡酯均可推荐使用。尽管有已发表的证据，奥氮平和托吡酯尚未获得任何药物监管机构用于ed的上市许可。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Biological Psychiatry 医学-精神病学

CiteScore

7.00

自引率

3.20%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of The World Journal of Biological Psychiatry is to increase the worldwide communication of knowledge in clinical and basic research on biological psychiatry. Its target audience is thus clinical psychiatrists, educators, scientists and students interested in biological psychiatry. The composition of The World Journal of Biological Psychiatry , with its diverse categories that allow communication of a great variety of information, ensures that it is of interest to a wide range of readers. The World Journal of Biological Psychiatry is a major clinically oriented journal on biological psychiatry. The opportunity to educate (through critical review papers, treatment guidelines and consensus reports), publish original work and observations (original papers and brief reports) and to express personal opinions (Letters to the Editor) makes The World Journal of Biological Psychiatry an extremely important medium in the field of biological psychiatry all over the world.